According to a May 21 decision summary issued by BBB National Programs, the NARB panel agreed that the clinical studies relied upon by Niagen Bioscience did not support certain “clinically proven” claims for the company’s Tru Niagen nicotinamide riboside (NR) and recommended that they be discontinued or modified.
The ruling centers on claims related to heart health, brain health, immune support, anti-aging and energy benefits associated with increases in NAD+ levels, highlighting a wider debate playing out across the supplement industry as brands increasingly lean on biomarker and cellular health science in consumer marketing.
As previously reported, the underlying case originated from a challenge brought by Reus Research LLC, now operating as Cata-Kor, against several express and implied Tru Niagen advertising claims.
NARB: Challenged claims conveyed broader health benefits
A central issue in the appeal was whether claims framed around cellular health and biological mechanisms also communicated real-world consumer outcomes.
In the decision summary, the panel stated that “the required substantiation depends on the message conveyed to consumers, not the advertiser’s regulatory classification.”
The panel further recommended that Niagen discontinue consumer testimonials and anti-aging claims that communicated “perceptible, real-world improvements,” as well as certain muscle health and energy claims suggesting functional recovery or vitality benefits.
Niagen Bioscience pushed back on that interpretation, with Carlos Lopez, senior vice president and general counsel at Niagen Bioscience, noting that the ruling “departs from over 30 years of bedrock law by dictating that structure-function claims require clinical proof of a perceptible, real-world improvement, rather than competent and reliable evidence of a nutrient’s role in the body.”
He added that “NARB does not dispute that Niagen elevates NAD+ and that NAD+ is essential for all cellular functions.”
Further, he explained that the company’s claims were intended to communicate support for healthy cellular functioning rather than to guarantee consumer outcomes.
Cata-Kor framed the issue differently.
“When a brand claims something is ‘clinically proven,’ consumers reasonably expect that the finished product at a relevant dose and use pattern has been tested and shown to deliver that result,” said Roman Miroedov, PhD, product development lead at Cata-Kor. “NARB’s ruling makes clear that how a company classifies a claim internally does not determine what consumers take away from it.”
What the ruling could mean for biomarker-driven research
Asa Waldstein, founder of Apex Compliance, said the decision reinforces the importance of connecting biomarker findings directly to the claims appearing in advertising.
“The key factor here is that the company should develop a defensible position paper that correlates the non-disease biomarker with the structure-function claim,” he said, noting that the level of scrutiny seen in the Tru Niagen case is common in highly competitive categories where companies closely monitor each other’s advertising claims.
“A key takeaway is that in a highly competitive area such as the NAD market, being extra careful to ensure that all claims, in all channels, including socials, have defensible position statements connecting the mechanism of action to the ingredient and structure-function claims,” he added.
Niagen, meanwhile, warned that the decision could undermine investments in clinical research.
“For companies investing heavily in biomarker-driven research, this decision has a chilling effect on innovation and may actively discourage future investments in human clinical trials,” Lopez said.
He also argued that the ruling signals a shift away from evaluating substantiation based on the totality of the evidence.
“By rejecting 10 gold-standard, double-blind, placebo-controlled human trials, this case unfortunately signals that self-regulatory bodies are abandoning the totality-of-evidence approach in favor of hyper-criticizing individual studies in isolation,” Lopez said.
Despite respectfully disagreeing with the NARB’s recommendations, Niagen stated that it will comply and review the broader advertising context of its claims.
Waldstein noted that although NAD and NARB proceedings are self-regulatory rather than formal FDA or FTC enforcement actions, companies still take the decisions seriously because of the potential for regulatory referrals and reputational risk.
